Sector News

J&J sells Cordis to Cardinal for $1.94bn

March 3, 2015
Life sciences
Healthcare giant Johnson & Johnson is selling its vascular med tech group Cordis to US drug distributer Cardinal Health for $1.94 billion, severing its ties with the field.
 
Cordis booked annual sales last year of around $780 million, split between cardiology and endovascular products, and Cardinal says it expects its acquisition to add more than $0.20 in earnings per share from fiscal 2017.
 
The move will significantly boost interventional cardiology and endovascular products, such as heart stents and catheters, Cardinal can offer hospitals and physicians, in line with a broader strategy of increasing its portfolio of medical device products.
 
“With an ageing population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best way to bring quality care to their patients in the most cost-effective way. The acquisition of Cordis reinforces our strategic position to address this need and strengthens an important growth driver in the Cardinal Health portfolio,” said chief executive George Barrett, further explaining the decision.
 
The deal, which Cardinal expects to fund with a combination of $1.0 billion in new senior unsecured notes and the remainder with existing cash, is expected to close in the US and key non-US countries towards the end of this year.
 
By Selina McKee
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.